---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-283108"
form_type: "8-K"
ticker: "CGON"
cik: "0001991792"
company_name: "CG Oncology, Inc."
filed_at: "2025-11-14T23:59:59+00:00"
generated_at: "2026-05-16T19:57:08.839963+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# CG Oncology CFO Robert Lapetina resigns; Jim DeTore named interim CFO effective Nov 17, 2025

## Summary
- Robert Lapetina resigned as interim principal financial and accounting officer, effective Nov 30, 2025.
- Jim DeTore appointed interim principal financial and accounting officer, effective Nov 17, 2025, via consulting agreement with Monomoy Advisors.
- DeTore to receive $32K for November (prorated) and $64K/month thereafter; initial term min 3 months, extendable 3 months.
- DeTore previously CFO at Neurogastrx (2021-2025) and Bluebird Bio (2014-2016); independent consultant 2017-2021.
- No family relationships or conflicts disclosed; DeTore eligible for standard indemnification agreement.

## SEC filing metadata
- accession: 0001193125-25-283108
- form_type: 8-K
- ticker: CGON
- cik: 0001991792
- company_name: CG Oncology, Inc.
- filed_at: 2025-11-14T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1991792/000119312525283108/0001193125-25-283108-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1991792/000119312525283108/ck0001991792-20251110.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-283108
- JSON: https://secwatch.observer/filing/0001193125-25-283108.json
- Plain text: https://secwatch.observer/filing/0001193125-25-283108.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.